(Q44685679)

5 December 2017

Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients (English)

1 reference

5 December 2017

1 reference

K Shiiba

1

1 reference

5 December 2017

R Suzuki

2

1 reference

5 December 2017

K Kawakami

3

1 reference

5 December 2017

A Ohuchi

4

1 reference

5 December 2017

K Kumagai

5

1 reference

5 December 2017

1 January 1986

1 reference

Cancer Immunology, Immunotherapy

5 December 2017

1 reference

5 December 2017

21

1 reference

5 December 2017

119-128

1 reference

5 December 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00199859

5 December 2017

0 references

cites work

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

Reduced lymphocyte transformation in breast cancer

1 reference

12 December 2020

Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

1 reference

12 December 2020

Tumor-associated specificity of serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors

1 reference

12 December 2020

Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells

1 reference

12 December 2020

Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production

1 reference

12 December 2020

Cytotoxic lymphocytes induced by soluble factors derived from the medium of leukocyte cultures

1 reference

12 December 2020

Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

1 reference

12 December 2020

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

1 reference

12 December 2020

Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

12 December 2020

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

12 December 2020

Serum-mediated immunosuppression in lung cancer

1 reference

12 December 2020

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

12 December 2020

Studies on cytotoxicity generated in human mixed lymphocyte cultures. I. Time course and target spectrum of several distinct concomitant cytotoxic activities

1 reference

12 December 2020

In vitro generation of cytotoxicity against autologous human tumour biopsy cells

1 reference

12 December 2020

Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo

1 reference

12 December 2020

Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens

1 reference

12 December 2020

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

1 reference

12 December 2020

Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells

1 reference

12 December 2020

Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00199859

1 reference

5 December 2017

1 reference